Intradermal Botulinum Toxin A for Melasma: A Randomized Split-Face Study Trial and In Vitro Study of Its Antimelanogenic Effect

IF 3.4 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2025-01-21 DOI:10.1155/dth/5550483

Wilai Thanasarnaksorn, Thanan Supasiri, Uraiwan Panich, Saowalak Thanachaiphiwat, Nuntida Salakshna

{"title":"Intradermal Botulinum Toxin A for Melasma: A Randomized Split-Face Study Trial and In Vitro Study of Its Antimelanogenic Effect","authors":"Wilai Thanasarnaksorn, Thanan Supasiri, Uraiwan Panich, Saowalak Thanachaiphiwat, Nuntida Salakshna","doi":"10.1155/dth/5550483","DOIUrl":null,"url":null,"abstract":"<div>\n Background: Melasma is a challenging hyperpigmentation disorder without absolute treatment.\n Aims: This study aimed to evaluate the effects of intradermal botulinum toxin A (BoNT-A) on melasma and the protective effects of BoNT-A on UVA-induced melanogenesis in B16F10 melanoma cells.\n Patients/Methods: This study is a split-face randomized, double-blind, placebo-controlled trial in 12 melasma patients who received intradermal abobotulinumtoxinA injection into melasma lesions. An in vitro study was also conducted in B16F10 melanoma cells treated with different concentrations of BoNT-A prior to exposure to UVA. Cell viability and cellular melanogenesis were determined.\n Results: The adjusted MASI scores on the BoNT-A side were significantly lower than the control at 3 months after injection, 2.8 versus 4.5 (p < 0.001), respectively. BoNT-A injection significantly reduced the MASI score at 2 and 3 months compared with the baseline of 4.1–3.2 (22%) (p < 0.001) and 2.8 (31.7%) (p < 0.001), respectively. Melanin content and tyrosinase activity in B16F10 cells with or without UVA irradiation were significantly reduced by treatment with BoNT-A in a dose-dependent manner without causing cytotoxicity.\n Conclusions: BoNT-A has a potentially beneficial effect in the treatment of melasma due to its antimelanogenic effect.\n Trial Registration: Clinical Trial Registry identifier: TCTR20250118001\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5550483","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/5550483","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Melasma is a challenging hyperpigmentation disorder without absolute treatment.

Aims: This study aimed to evaluate the effects of intradermal botulinum toxin A (BoNT-A) on melasma and the protective effects of BoNT-A on UVA-induced melanogenesis in B16F10 melanoma cells.

Patients/Methods: This study is a split-face randomized, double-blind, placebo-controlled trial in 12 melasma patients who received intradermal abobotulinumtoxinA injection into melasma lesions. An in vitro study was also conducted in B16F10 melanoma cells treated with different concentrations of BoNT-A prior to exposure to UVA. Cell viability and cellular melanogenesis were determined.

Results: The adjusted MASI scores on the BoNT-A side were significantly lower than the control at 3 months after injection, 2.8 versus 4.5 (p < 0.001), respectively. BoNT-A injection significantly reduced the MASI score at 2 and 3 months compared with the baseline of 4.1–3.2 (22%) (p < 0.001) and 2.8 (31.7%) (p < 0.001), respectively. Melanin content and tyrosinase activity in B16F10 cells with or without UVA irradiation were significantly reduced by treatment with BoNT-A in a dose-dependent manner without causing cytotoxicity.

Conclusions: BoNT-A has a potentially beneficial effect in the treatment of melasma due to its antimelanogenic effect.

Trial Registration: Clinical Trial Registry identifier: TCTR20250118001

Abstract Image

查看原文本刊更多论文

黄褐斑皮内肉毒毒素A：一项随机裂面研究试验及其抗黑素生成作用的体外研究

背景：黄褐斑是一种具有挑战性的色素沉着症，没有绝对的治疗方法。目的：本研究旨在评价皮内肉毒毒素A （BoNT-A）对黄褐斑的作用以及BoNT-A对uva诱导的B16F10黑色素瘤细胞黑色素生成的保护作用。患者/方法：本研究是一项裂面随机、双盲、安慰剂对照试验，12名黄褐斑患者接受黄褐斑病变皮内肉毒杆菌毒素注射。在暴露于UVA之前，用不同浓度的BoNT-A处理过的B16F10黑色素瘤细胞也进行了一项体外研究。测定细胞活力和细胞黑色素生成情况。结果：注射后3个月BoNT-A侧调整后MASI评分显著低于对照组，分别为2.8和4.5 (p <；分别为0.001)。与基线4.1-3.2相比，BoNT-A注射显著降低了2个月和3个月MASI评分（22%）(p <；0.001)和2.8 (31.7%)(p <；分别为0.001)。用BoNT-A以剂量依赖的方式处理UVA照射或不照射的B16F10细胞，黑色素含量和酪氨酸酶活性显著降低，而不引起细胞毒性。结论：BoNT-A由于其抗黑素生成的作用，在治疗黄褐斑方面具有潜在的有益作用。试验注册：临床试验注册标识：TCTR20250118001

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.